Patterns of failure and the subsequent treatment after progression on first-line immunotherapy monotherapy in advanced non-small cell lung cancer: a retrospective study.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have become the recommended first-line treatment for advanced non-small cell lung cancer (NSCLC) without driver gene mutations. However, data on the failure patterns of first-line ICIs monotherapy is limited, and the optimal strategy for subsequent treatment remains controversial.

Methods

Advanced NSCLC patients receiving first-line ICIs monotherapy at Guangdong Lung Cancer Institute between December 2017 and October 2021 were identified. The progressive sites were recorded to analyze failure patterns. Post-progression survival (PPS) was compared between different treatment regimens.

Results

A total of 121 patients receiving first-line ICIs monotherapy were identified, with a median progression-free survival of 8.6 months

SUBMITTER: Deng JY 

PROVIDER: S-EPMC11438227 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature